Macugen Advisory Committee To Discuss Concomitant Use With Visudyne
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will discuss concomitant use of Pfizer/Eyetech's Macugen and Novartis/QLT's Visudyne (verteporfin) at an Aug. 27 meeting